close
close

Tag: mucormycosis

European Commission decision to approve the pediatric use of the antifungal Cresemba® (isavuconazole) and to extend market exclusivity triggers milestone payment of CHF 10 million to Basilea

Posted on | Posted on Jasper | Leave a Comment on European Commission decision to approve the pediatric use of the antifungal Cresemba® (isavuconazole) and to extend market exclusivity triggers milestone payment of CHF 10 million to Basilea
European Commission decision to approve the pediatric use of the antifungal Cresemba® (isavuconazole) and to extend market exclusivity triggers milestone payment of CHF 10 million to Basilea

Basilea Pharmaceutica AG, Allschwil Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, August 27, 2024 Basilea Pharmaceutica AG, Allschwil (SIX: BSLN), a biopharmaceutical company focused on the needs of patients with severe bacterial and fungal infections, today announced that the European Commission (EC) has expanded the indications for the antifungal Cresemba.® (isavuconazole) for […]